Phytochemical investigation of Ixeris chinensis NAKAI (Asteraceae) has resulted in the isolation of a new guaianolide-type sesquiterpene lactone, ixerochinolide (1) as well as the related glucoside, ixerochinoside (2). In addition, the known guaianolides, 8b b-hydroxy-3-oxo-guaia-4(15),10(14),11(13)-trien-1a a,5a a,6b b,7a aH-12,6-olide (8b b-hydroxydehydrozaluzanin), 8b b,15-dihydroxy-2-oxo-guaia-1(10),3,11(13)-trien-5a a,6b b,7a aH-12,6-olide (lactucin), 3b b,8a a,10a a-trihydroxy-guaia-4(15),11(13)-dien-1a a,5a a,6b b,7a aH-12,6-olide (10a a-hydroxy-10,14-dihydro-desacylcynaropicrin) and 3b b-D-glucopyranosyloxy-8b b-(p-hydroxyphenylacetyloxy)-guaia-4(15),10(14),11(13)-trien1a a,5a a,6b b,7a aH-12,6-olide (8-epicrepioside) were identified. The structures were determined on the basis of spectral analyses, especially 1-and 2D NMR. Compound 1 exhibited significant cytotoxicity against human PC-3 tumor cells.
Ixeris chinensis NAKAI (Asteraceae) is a medicinal Chinese herb used for treatment of bronchitis, pneumonia, dysentery as well as for its antipyretic, analgesic and anti-inflammatory effects. 1) As many Asteraceaous plants, this species is rich in sesquiterpene lactones with diverse biological activities [2] [3] [4] such as immunomodulator 5) and cytotoxic effects. 6) Their biological activities have been attributed to their reactivity with the cysteine residues of functional proteins forming covalent bonds. 7) Six guaianolides 8, 9) in addition to forty triterpenoids 10, 11) were previously isolated from this species. The present study is concerned with the isolation and structural elucidation of two new guaianolides, ixerochinolide (1) and a related glucoside, ixerochinoside (2) . During the course of fractionation, four known guaianolides, 8b-hydroxy-3-oxoguaia-4(15), 10(14) ,11(13)-trien-1a ,5a ,6b ,7a H-12,6-olide (8b-hydroxydehydrozaluzanin), 8b,15-dihydroxy-2-oxo-guaia-1(10),3,11(13)-trien-5a,6b,7aH-12,6-olide (lactucin), 3b,8a, 10a -trihydroxy-guaia-4(15),11(13)-dien-1a ,5a ,6b ,7a H-12,6-olide (10a-hydroxy-10,14-dihydro-desacylcynaropicrin) and 3b-D-glucopyranosyloxy-8b-(p-hydroxyphenylacetyloxy)-guaia-4(15), 10(14) ,11(13)-trien-1a 5a ,6b ,7a H-12,6-olide (8-epicrepioside) were identified. The structures of these bitter-tasting compounds were elucidated through detailed studies of the spectral data especially 1-and 2D NMR. The cytotoxic activity of the isolated guaianolides was tested against human PC-3 tumor cells.
Results and Discussion
Chromatographic fractionation of the acetone extract of Ixeris chinensis NAKAI has led to the isolation of six guaianolide derivatives. The HR-ESI-MS of 1 revealed a quasi-molecular ion peak at m/z 419.1474 [MϩNa] ϩ consistent with the molecular formula C 23 H 24 O 6 and twelve degrees of unsaturation. The IR spectrum showed absorption bands characteristic of a hydroxyl (3405 cm downfield shift of H-8 (d 5.43) was attributed to the attachment of the ester moiety that was proved by HMBC correlation between H-8 and the carbonyl ester signal at d 171.1. Furthermore, the HMBC spectrum exhibited correlations between H-3/C-15; H-7/C-5, C-13; H-8/C-10; H-14/C-1. Contrary to the case of hydroxyl or a-acyloxy substitution at C-8, the minute coupling constant of J 7,8 (1.8 Hz) implied the a-configuration of both H-7 and H-8 that was in accordance with the results obtained from a molecular model. [15] [16] [17] The strong NOESY correlations between H-8/H-7a as well as between H-5a/H-1, H-3 and H-7 confirmed the a-configuration of both H-8 and H-3. The NMR data as well as the sign of optical rotation of 1 were in good agreement with those reported for integrifolin and its derivatives. 9, 14, 17, 18) Consequently, the structure of 1 was formulated as 3b-hydroxy-8b-(p-hydroxyphenylacetyloxy)-guaia-4(15),10(14),11(13)-trien1a,5a,6b,7aH-12,6-olide or 8-O-p-hydroxyphenylacetyl integrifolin, and it was named ixerochinolide.
Compound 2 Table 1) to those of 3b-(b-D-glucopyranosyloxy)-8b -(4Љ-methoxyphenylacetoxy)-guaia-4(15),10(14),11(13)-trien-1a,5a,6b,7aH-12,6-olide 19) supported the proposed configuration at the former positions. The HMBC correlation between the anomeric signal at d 4.36 (H-1Љ) and a carbon signal at d 81.9 (C-3) located the sugar moiety at C-3. The second p-hydroxyphenylacetic acid ester was located at C-6Љ of the D-glucose moiety as deduced from the HMBC correlations between both signals of H-6Љ (d 4.21, 4.47) and the carbonyl signal of the ester at d 173.6 (Fig. 1) . From the above-mentioned data, the structure of ixerochinoside (2) was established as 3b-(6Љ-phenylacetyloxyb -D-glucopyranosyloxy)-8b -(p-hydroxyphenylacetyloxy)-guaia-4(15),10(14),11(13)-trien-1a,5a,6b,7aH-12, 6-olide.
The known compounds 8b-hydroxydehydro-zaluzanin, 15, 17) lactucin, 20) 10a-hydroxy-10,14-dihydrodesacylcynaropicrin, 21) 8-epicrepioside 9) were identified through direct comparison with published data. The in vitro cytotoxicity of the isolated sesquiterpenes were evaluated against human prostate (PC-3) tumor cells. As illustrated in Table 2 , compound 1 exhibited significant growth inhibition against PC-3 cells at IC 50 of 1.6 mg/ml. However, other compounds were very weak or inactive in this screen system.
Experimental
Optical rotations were recorded on a JASCO DIP-1000 polarimeter. IR and UV spectra were measured on Hitachi T-2001 and Hitachi U-3210 spectrophotometers, respectively. Low-resolution EI-MS and FAB-MS spectra were recorded on a VG Quattro 5022 mass spectrometer. High-resolution ESI-MS spectra were measured on a JEOL HX 110 mass spectrometer. The Extraction and Isolation The powdered whole plant (1900 g) was extracted three times with acetone (3ϫ5 l). The concentrated extract was partitioned between EtOAc and H 2 O to produce an aqueous and an EtOAc layers. The latter, after removing the solvent under vacuum, was shaken four times with a mixture of n-hexane/MeOH/H 2 O (4 : 3 : 1) in a separating funnel and the lower hydroalcoholic layer was concentrated to a syrup (300 ml) and re-extracted with EtOAc (4ϫ400 ml). The resulting EtOAc extract (8.5 g) was flash-chromatographed on silica gel using a gradient mixture of CH 2 Cl 2 /MeOH to furnish eight fractions. Fractions 3 (300 mg) was chromatographed on a silica gel column using a gradient of n-hexane/acetone followed by purification on silica gel PTLC using n-hexane/EtOAc (3 : 1) to yield 1 (19 mg) and 8b-hydroxydehydrozaluzanin (2 mg). Fraction 4 (570 mg) was repeatedly chromatographed on a silica gel column using a gradient of n-hexane/acetone followed by PTLC on silica gel plates using CH 2 Cl 2 / MeOH (95 : 5) to furnish lactucin (3 mg) and 10a-hydroxy-10,14-dihydrodesacylcynaropicrin (2 mg). Fraction 5 (750 mg) was chromatographed on a silica gel column using a gradient of CH 2 Cl 2 /MeOH to give 2 (56 mg). Chromatography of fraction 7 (4 g) on silica gel column using a gradient of CH 2 Cl 2 /MeOH yielded 8-epicrepioside (1900 mg).
Compound (1) The human PC-3 (prostate) cancer cell line of the screening panel are grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine. Cells are inoculated into 96 well microtiter plates in 100 mg at plating densities ranging from 5000 to 40000 cells/well depending on the doubling time of individual cell lines. After cell inoculation, the microtiter plates are incubated at 37°C, 5% CO 2 , 95% air and 100% relative humidity for 24 h prior to addition of experimental drugs. After 24 h, two plates of each cell line are fixed in situ with TCA, to represent a measurement of the cell population for each cell line at the time of drug addition. Experimental drugs are solubilized in dimethyl sulfoxide at 400-fold the desired final maximum test concentration and stored frozen prior to use. At the time of drug addition, an aliquot of frozen concentrate is thawed and diluted to twice the desired final maximum test concentration with complete medium containing 50 mg/ml gentamicin. Additional four, 10-fold or 1/2 log serial dilutions are made to provide a total of five drug concentrations plus control. Aliquots of 100 ml of these different drug dilutions are added to the appropriate microtiter wells already containing 100 ml of medium, resulting in the required final drug concentrations. Following drug addition, the plates are incubated for an additional 48 h at 37°C, 5% CO 2 , 95% air and 100% relative humidity. For adherent cells, the assay is terminated by the addition of cold TCA. Cells are fixed in situ by the gentle addition of 50 ml of cold 50% (w/v) TCA (final concentration, 10% TCA) and incubated for 60 min at 4°C. The supernatant is discarded, and the plates are washed five times with tap water and air-dried. Sulforhodamine B (SRB) solution (100 ml) at 0.4% (w/v) in 1% acetic acid is added to each well, and plates are incubated for 10 min at room temperature. After staining, unbound dye is removed by washing five times with 1% acetic acid and the plates are air dried. Bound stain is subsequently solubilized with 10 mM trizma base, and the absorbance is read on an automated plate reader at a wavelength of 515 nm. Paclitaxel was used as standard.
